FUS is sequestered in nuclear aggregates in ALS patient fibroblasts

Molecular Biology of the Cell

Volumn 25, Issue 17, 2014, Pages 2571-2578

  Schwartz, Jacob C ^a   Podell, Elaine R ^a   Han, Steve S W ^b,c   Berry, James D ^b   Eggan, Kevin C ^c   Cech, Thomas R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Harvard University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUSED IN SARCOMA PROTEIN; RNA POLYMERASE II; SERINE; SMALL INTERFERING RNA; PROTEIN AGGREGATE; RNA BINDING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CONTROLLED STUDY; FIBROBLAST; GENE MUTATION; GENETIC ASSOCIATION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; NUCLEAR LOCALIZATION SIGNAL; POINT MUTATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION SITE; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL NUCLEUS; GENETICS; METABOLISM; PHOSPHORYLATION; RNA INTERFERENCE;

AMYOTROPHIC LATERAL SCLEROSIS; CELL NUCLEUS; CELLS, CULTURED; FIBROBLASTS; HUMANS; PHOSPHORYLATION; PROTEIN AGGREGATES; RNA INTERFERENCE; RNA POLYMERASE II; RNA-BINDING PROTEIN FUS; TRANSCRIPTION INITIATION SITE;

EID: 84907192512     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E14-05-1007     Document Type: Article

References (51)

1. Alliegro MC, Alliegro MA (1996). A nuclear protein regulated during the transition from active to quiescent phenotype in cultured endothelial cells. Dev Biol 174, 288-297.
2. Bachmaier R, Aryee DN, Jug G, Kauer M, Kreppel M, Lee KA, Kovar H (2009). O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma. Oncogene 28, 1280-1284.
3. Bosco DA, Lemay N, Ko HK, Zhou H, Burke C, Kwiatkowski TJ Jr, Sapp P, McKenna-Yasek D, Brown RH Jr, Hayward LJ (2010). Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum Mol Genet 19, 4160-4175.
4. Calvio C, Neubauer G, Mann M, Lamond AI (1995). Identification of hnRNP P2 as TLS/FUS using electrospray mass spectrometry. RNA 1, 724-733.
5. Cisse II, Izeddin I, Causse SZ, Boudarene L, Senecal A, Muresan L, Dugast-Darzacq C, Hajj B, Dahan M, Darzacq X (2013). Real-time dynamics of RNA polymerase II clustering in live human cells. Science 341, 664-667.
6. Crozat A, Aman P, Mandahl N, Ron D (1993). Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 363, 640-644.
7. Das R, Yu J, Zhang Z, Gygi MP, Krainer AR, Gygi SP, Reed R (2007). SR proteins function in coupling RNAP II transcription to pre-mRNA splicing. Mol Cell 26, 867-881.
8. Fujii R, Okabe S, Urushido T, Inoue K, Yoshimura A, Tachibana T, Nishikawa T, Hicks GG, Takumi T (2005). The RNA binding protein TLS is translocated to dendritic spines by mGluR5 activation and regulates spine morphology. Curr Biol 15, 587-593.
9. Fujii R, Takumi T (2005). TLS facilitates transport of mRNA encoding an actin-stabilizing protein to dendritic spines. J Cell Sci 118, 5755-5765.
10. Glover-Cutter K, Kim S, Espinosa J, Bentley DL (2008). RNA polymerase II pauses and associates with pre-mRNA processing factors at both ends of genes. Nat Struct Mol Biol 15, 71-78.
11. Gu B, Eick D, Bensaude O (2013). CTD serine-2 plays a critical role in splicing and termination factor recruitment to RNA polymerase II in vivo. Nucleic Acids Res 41, 1591-1603.
12. Hackl W, Luhrmann R (1996). Molecular cloning and subcellular localisation of the snRNP-associated protein 69KD, a structural homologue of the proto-oncoproteins TLS and EWS with RNA and DNA-binding properties. J Mol Biol 264, 843-851.
13. Halliday G, Bigio EH, Cairns NJ, Neumann M, Mackenzie IR, Mann DM (2012). Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. Acta Neuropathol 124, 373-382.
14. Hallier M, Lerga A, Barnache S, Tavitian A, Moreau-Gachelin F (1998). The transcription factor Spi-1/PU.1 interacts with the potential splicing factor TLS. J Biol Chem 273, 4838-4842.
15. Hoell JI, Larsson E, Runge S, Nusbaum JD, Duggimpudi S, Farazi TA, Hafner M, Borkhardt A, Sander C, Tuschl T (2011). RNA targets of wild-type and mutant FET family proteins. Nat Struct Mol Biol 18, 1428-1431.
16. Iko Y, Kodama TS, Kasai N, Oyama T, Morita EH, Muto T, Okumura M, Fujii R, Takumi T, Tate S, et al. (2004). Domain architectures and characterization of an RNA-binding protein, TLS. J Biol Chem 279, 44834-44840.
17. Immanuel D, Zinszner H, Ron D (1995). Association of SARFH (sarcoma-associated RNA-binding fly homolog) with regions of chromatin transcribed by RNA polymerase II. Mol Cell Biol 15, 4562-4571.
18. Ishigaki S, Masuda A, Fujioka Y, Iguchi Y, Katsuno M, Shibata A, Urano F, Sobue G, Ohno K (2012). Position-dependent FUS-RNA interactions regulate alternative splicing events and transcriptions. Sci Rep 2, 529.
19. Kabashi E, Bercier V, Lissouba A, Liao M, Brustein E, Rouleau GA, Drapeau P (2011). FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLoS Genet 7, e1002214.
20. Kato M, Han TW, Xie S, Shi K, Du X, Wu LC, Mirzaei H, Goldsmith EJ, Longgood J, Pei J, et al. (2012). Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell 149, 753-767.
21. Kim H, Erickson B, Luo W, Seward D, Graber JH, Pollock DD, Megee PC, Bentley DL (2010). Gene-specific RNA polymerase II phosphorylation and the CTD code. Nat Struct Mol Biol 17, 1279-1286.
22. Kino Y, Washizu C, Aquilanti E, Okuno M, Kurosawa M, Yamada M, Doi H, Nukina N (2010). Intracellular localization and splicing regulation of FUS/TLS are variably affected by amyotrophic lateral sclerosis-linked mutations. Nucleic Acids Res 39, 2781-2798.
23. Kuroda M, Sok J, Webb L, Baechtold H, Urano F, Yin Y, Chung P, de Rooij DG, Akhmedov A, Ashley T, et al. (2000). Male sterility and enhanced radiation sensitivity in TLS(-/-) mice. EMBO J 19, 453-462.
24. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, et al. (2009). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205-1208.
25. Kwon I, Kato M, Xiang S, Wu L, Theodoropoulos P, Mirzaei H, Han T, Xie S, Corden JL, McKnight SL (2013). Phosphorylation-regulated binding of RNA polymerase II to fibrous polymers of low-complexity domains. Cell 155, 1049-1060.
26. Lagier-Tourenne C, Polymenidou M, Hutt KR, Vu AQ, Baughn M, Huelga SC, Clutario KM, Ling SC, Liang TY, Mazur C, et al. (2012). Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci 15, 1488-1497.
27. Lattante S, Rouleau GA, Kabashi E (2013). TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum Mutat 34, 812-826.
28. Lerga A, Hallier M, Delva L, Orvain C, Gallais I, Marie J, Moreau-Gachelin F (2001). Identification of an RNA binding specificity for the potential splicing factor TLS. J Biol Chem 276, 6807-6816.
29. Mackenzie IR, Munoz DG, Kusaka H, Yokota O, Ishihara K, Roeber S, Kretzschmar HA, Cairns NJ, Neumann M (2011). Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol 121, 207-218.
30. Mayer A, Lidschreiber M, Siebert M, Leike K, Soding J, Cramer P (2010). Uniform transitions of the general RNA polymerase II transcription complex. Nat Struct Mol Biol 17, 1272-1278.
31. Meissner M, Lopato S, Gotzmann J, Sauermann G, Barta A (2003). Proto-oncoprotein TLS/FUS is associated to the nuclear matrix and complexed with splicing factors PTB, SRm160, and SR proteins. Exp Cell Res 283, 184-195.
32. Mo X, Dynan WS (2002). Subnuclear localization of Ku protein: functional association with RNA polymerase II elongation sites. Mol Cell Biol 22, 8088-8099.
33. Munoz MJ, Perez Santangelo MS, Paronetto MP, de la Mata M, Pelisch F, Boireau S, Glover-Cutter K, Ben-Dov C, Blaustein M, Lozano JJ, et al. (2009). DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell 137, 708-720.
34. Powers CA, Mathur M, Raaka BM, Ron D, Samuels HH (1998). TLS (translocated-in-liposarcoma) is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors. Mol Endocrinol 12, 4-18.
35. Scaramuzzino C, Monaghan J, Milioto C, Lanson NA Jr, Maltare A, Aggarwal T, Casci I, Fackelmayer FO, Pennuto M, Pandey UB (2013). Protein arginine methyltransferase 1 and 8 interact with FUS to modify its sub-cellular distribution and toxicity in vitro and in vivo. PLoS One 8, e61576.
36. Schwartz JC, Ebmeier CC, Podell ER, Heimiller J, Taatjes DJ, Cech TR (2012). FUS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2. Genes Dev 26, 2690-2695.
37. Schwartz JC, Wang X, Podell ER, Cech TR (2013). RNA seeds higher-order assembly of FUS protein. Cell Rep 5, 918-925.
38. Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, Gitler AD (2011). Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol 9, e1000614.
39. Tan AY, Manley JL (2010). TLS inhibits RNA polymerase III transcription. Mol Cell Biol 30, 186-196.
40. Tan AY, Riley TR, Coady T, Bussemaker HJ, Manley JL (2012). TLS/FUS (translocated in liposarcoma/fused in sarcoma) regulates target gene transcription via single-stranded DNA response elements. Proc Natl Acad Sci USA 109, 6030-6035.
41. Tradewell ML, Yu Z, Tibshirani M, Boulanger MC, Durham HD, Richard S (2012). Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations. Hum Mol Genet 21, 136-149.
42. Tsuiji H, Iguchi Y, Furuya A, Kataoka A, Hatsuta H, Atsuta N, Tanaka F, Hashizume Y, Akatsu H, Murayama S, et al. (2013). Spliceosome integrity is defective in the motor neuron diseases ALS and SMA. EMBO Mol Med 5, 221-234.
43. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, et al. (2009). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-1211.
44. Vance C, Scotter EL, Nishimura AL, Troakes C, Mitchell JC, Kathe C, Urwin H, Manser C, Miller CC, Hortobagyi T, et al. (2013). ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Hum Mol Genet 22, 2676-2688.
45. Wang X, Arai S, Song X, Reichart D, Du K, Pascual G, Tempst P, Rosenfeld MG, Glass CK, Kurokawa R (2008). Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature 454, 126-130.
46. Yamaguchi A, Kitajo K (2012). The effect of PRMT1-mediated arginine methylation on the subcellular localization, stress granules, and detergent-insoluble aggregates of FUS/TLS. PLoS One 7, e49267.
47. Yamazaki T, Chen S, Yu Y, Yan B, Haertlein TC, Carrasco MA, Tapia JC, Zhai B, Das R, Lalancette-Hebert M, et al. (2012). FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. Cell Rep 2, 799-806.
48. Yang L, Chansky HA, Hickstein DD (2000). EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J Biol Chem 275, 37612-37618.
49. Zhu X, Zeng X, Huang B, Hao S (2004). Actin is closely associated with RNA polymerase II and involved in activation of gene transcription. Biochem Biophys Res Commun 321, 623-630.
50. Zinszner H, Albalat R, Ron D (1994). A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev 8, 2513-2526.
51. Zinszner H, Sok J, Immanuel D, Yin Y, Ron D (1997). TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J Cell Sci 110, 1741-1750.